Bio-Rad Laboratories Inc. (BIO)$287.74
Market Cap: 6.53 BCurrency: USD
Research Snapshot
Static fundamentals, valuation context, and investor signals for Bio-Rad Laboratories Inc. (BIO).
HEALTHCARE
MEDICAL DEVICES
DCF ready
Valuation
19.2x
EV/FCF, 5.2% FCF yield
Quality
8.8%
ROIC, 14.5% FCF margin
Growth
0.3%
5Y sales (revenue) CAGR
Balance sheet
0.2x
Debt/equity, 5.6x current ratio
Superinvestors
5
Top: Charles Bobrinskoy (3.1%)
Strengths to research
- Free cash flow margin is healthy at 14.5%.
- Debt/equity looks manageable at 0.2x.
- 5 tracked superinvestors report a position.
- 10 annual periods are available for trend analysis.
Watchouts
No major valuation, balance sheet, or growth watchouts were detected by the static screen.
Annual data: 10 periods
Quarterly data: 24 periods
Stock snapshot: May 25, 2026
Static dataset: May 25, 2026
Quality Scorecard
Build-time composite score for BIO.
Grade D
35
/ 100
Peer Comparison
Target stock against 8 market-cap comparable peers.
Heat map: red worst to green best
| BIO Target | Bio-Rad Laboratories Inc. | $6.5B | 10.3x | 19.2x | 8.8% | 0.3% | 14.5% | 51.9% | 3.2x | N/A |
| BRKR | Bruker Corp. | $6.2B | -304.6x | 178.8x | -0.2% | 11.6% | 1.3% | 45.9% | 5.4x | N/A |
| ITGR | Integer Holdings Corp. | $4.1B | 30.9x | 49.8x | 3.5% | 11.5% | 5.7% | 27.0% | 3.3x | N/A |
| LIVN | LivaNova PLC | $2.0B | -16.6x | 9.9x | -15.4% | 8.2% | 12.5% | 67.7% | -1.1x | N/A |
| ENOV | Enovis Corp. | $2.0B | -1.2x | 161.2x | -42.5% | 14.9% | 0.9% | 59.8% | 5.7x | N/A |
| STE | STERIS plc | $22.0B | 34.9x | 30.6x | 7.2% | 12.5% | 14.3% | 44.0% | 1.3x | N/A |
| QDEL | QuidelOrtho Corp. | $1.9B | -0.7x | -53.0x | -24.5% | 10.4% | -3.0% | N/A | N/A | N/A |
| DXCM | DEXCOM, INC. | $31.5B | 34.5x | 28.4x | 30.5% | 19.3% | 23.1% | 60.1% | -0.8x | N/A |
| AHCO | AdaptHealth Corp. | $1.2B | -20.1x | 12.8x | -2.2% | 25.2% | 6.8% | N/A | 3.4x | N/A |
Financial Charts
No financial data available for BIO (annual).
5 superinvestors own BIO
Current quarter ownership and quarter-over-quarter share changes.
Superinvestor ownership
| Fund | Shares | Value | % Portfolio | QoQ Change |
|---|---|---|---|---|
| First Eagle Investment Management First Eagle Investment Management | 2,602,772 | $726M | 1.23% | 0.0% |
| John Rogers Ariel Appreciation Fund | 785,961 | $219M | 2.45% | 0.0% |
| Steven Romick FPA Crescent Fund | 236,916 | $58M | 1.01% | ▼ -2.9% |
| Mason Hawkins Longleaf Partners | 162,804 | $45M | 2.23% | 0.0% |
| Charles Bobrinskoy Ariel Focus Fund | 6,213 | $2M | 3.10% | New |